LevitasBio, a Menlo Park, CA-based provider of a processing and analysis solutions for life sciences market, raised $35M in Series C funding.
The round was led by Novalis Lifesciences with participation from Pavilion Capital, and Decheng Capital.
The company intends to use the funds to accelerate its commercial efforts through the development of instruments for sample processing and analysis.
Led by CEO Martin Pieprzyk, LevitasBio provides proprietary label-free levitation technology which enables researchers to examine, analyze and understand biological signatures without altering, stressing, or damaging cells—all while preserving the original samples.
Over the last year, LevitasBio expanded its portfolio with multiple product developments:
- LeviPrep—novel and empowering cold tissue dissociation kits
- LeviSelect—specific surface marker enrichment assays
- LeviCell EOS System—next generation sample processing platform with higher throughput and temperature control
- LeviMetrics—integrated analysis software for real-time on-platform analysis
FinSMEs
07/11/2022